Karyopharm Therapeutics
Pietro Taverna is an accomplished executive in translational medicine, currently serving as Vice President of Research & Translational Medicine at Karyopharm Therapeutics Inc. since February 2023. Prior to this role, Pietro held senior leadership positions, including Executive Director of Translational Sciences at Constellation Pharmaceuticals and Vice President of Translational Medicine & Nonclinical Development at Sunesis Pharmaceuticals. Pietro's extensive experience encompasses strategic oversight of clinical development for various oncology treatments, with notable contributions to Vecabrutinib and SNS-510. Former roles at Astex Pharmaceuticals and Chiron Corp. involved leading translational pharmacology efforts for novel cancer therapies. Educational qualifications include a PhD in Pharmacological Research and postdoctoral training from prestigious institutions.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).